- Reaction score
- 1,332
:\ Sad, it's always delayed....we have to find ourselves what is the topical they use in order to do this follicle neogenesis
It's likely you'll find out the "topical" or "active ingredient" when their study is up.
:\ Sad, it's always delayed....we have to find ourselves what is the topical they use in order to do this follicle neogenesis
This last trial will take how much time?
2019/2020 we can just get tsuji treatment and do not need follica anymore Really sad. Let´s just hope for Brotzu, really last hope until 2020. Replicel won´t be a solution for high norwoods.
True, sure I am happy if they bring something to market and follica itself too for sure, because they could make more money as a single player on the market. But still, I was hoping for an earlier release.
But now what do we have?
it is really depressing waiting another 4-5 years for any treatment
I really hope fidia is just having stability problems .......
The average Phase III trial last 17 months, and Follica hasn't even started yet. There's no way they release in 2019.
But what about their compound?It isn't going to be a phase 3 trial in the traditional sense like you think. They'll be aiming for 501K approval. It's a medical device after all.
But what about their compound?
Not if there's a novel compound involved. Do you have a source for that?
There isn't going to be any novel compound. It has to be a compound that is already approved on the market due to obvious reasons. Most likely one or more that are off-patent (could be a combination of compounds)
Sure: http://puretechhealth.com/images/investors/Puretech_Pi_e-Prospectus_Final_T08_CNB-v2.pdf
"Thereafter, Follica plans to seek FDA 510(k) clearance using data from a pivotal clinical trial at multiple clinical sites within and potentially also outside the US. The pivotal trial for the in-office procedure is expected to be initiated during 2016 and would be expected to complete in 2017"
You mean 10,000 people per year?If it comes out in 2020: it will only be in Japan, they said they aim to treat just 10,000 people globally and it will definitely cost a fortune.
If sheisido shows solid efficacy, why can't replicel utilize the 21st century cures act to release early in America? Have they done any phase trials in America, or have they only done them in BC?
You mean 10,000 people per year?
Shiseido will show solid efficacy because it's the same tech as RepliCel and RepliCel can't utilize the 21st Century cures act because RepliCel has the organizational skills and punctuality of a one-eyed man with cataracts charged with alphabetizing the Hogwarts' Library and who also has no fuckin' legs to get there anyway.
That's what they said in the interview this site did with Organ Tech.
So only 10000 people a year will get the treatment or only 10000 ever? Im so confusedShiseido will show solid efficacy because it's the same tech as RepliCel and RepliCel can't utilize the 21st Century cures act because RepliCel has the organizational skills and punctuality of a one-eyed man with cataracts charged with alphabetizing the Hogwarts' Library and who also has no fuckin' legs to get there anyway.
That's what they said in the interview this site did with Organ Tech.
So only 10000 people a year will get the treatment or only 10000 ever? Im so confused
Ohh okay that sounds about right I was gonna be pissed if they only did 10000 ever lol but hey guys if u win the lotteey ill be glad to pay for all of your hair transplants with TisujiiThey're projection is 10,000/year I assume till they can scale it better
This information is making it so confusing so then are we expecting it to be completed or did they not even start? LolThere isn't going to be any novel compound. It has to be a compound that is already approved on the market due to obvious reasons. Most likely one or more that are off-patent (could be a combination of compounds)
Sure: http://puretechhealth.com/images/investors/Puretech_Pi_e-Prospectus_Final_T08_CNB-v2.pdf
"Thereafter, Follica plans to seek FDA 510(k) clearance using data from a pivotal clinical trial at multiple clinical sites within and potentially also outside the US. The pivotal trial for the in-office procedure is expected to be initiated during 2016 and would be expected to complete in 2017"